Looming pharmaceutical tariffs may temporarily dampen biotech dealmaking, but investors remain bullish on the sector's long-term tailwinds.
Driving the news: President Trump on Monday announced a Commerce Department probe into drug imports, just a week after floating "major" pharma tariffs.
